MedPath

The Effect of Remimazolam on Opioid Induced Hyperalgesia

Not Applicable
Completed
Conditions
Hyperalgesia, Mechanical
Interventions
Registration Number
NCT05866315
Lead Sponsor
Wonkwang University Hospital
Brief Summary

The goal of this prospective, randomized, controlled study is to investigate the effect of remimazolam on opioid-induced hyperalgesia (OIH) in patients undergoing single port-laparoscopically assisted urologic surgery.

The main question\[s\] it aims to answer are:

* \[The mechanical hyperalgesia threshold\]

* \[Area of hyperalgesia around the surgical incision 24 h after surgery (cm\^2)\]

In three groups: Group RHR (Remimazolam- High-dose Remifentanil), Group DHR (Desflurane-low-dose Remifentanil) or Group DLR (Control).

Detailed Description

Ninety-three (n = 31 per group) American Society of Anesthesiologists I-II patients (age 20-65 years) will be scheduled for single port-laparoscopically assisted urologic surgery.

Group RHR (Remimazolam-Remifentanil): Administer remimazolam at a dose of 6 mg/kg/h initially, followed by 1 mg/kg/h, and remifentanil at 0.3 µg/kg/min.

Group DHR (Desflurane-Remifentanil): Administer desflurane at 1 minimum alveolar concentration (MAC), adjusting the dose by 1 vol% titration to maintain MAP and BIS levels, and remifentanil at 0.3 µg/kg/min.

Group DLR (Control): Administer desflurane at 1 MAC, adjust the dose by 1 vol% titration to maintain mean arterial pressure (MAP) and bispectral index (BIS) levels, and remifentanil at 0.3 µg/kg/min.

Mechanical hyperalgesia threshold, Time to first postoperative analgesic requirement (min), Injected PCA volume containing morphine for 12 h after surgery (ml), Pain intensity: VAS 1 h after surgery, VAS 6 h after surgery, VAS 12 h after surgery VAS 24 h after surgery. Area of hyperalgesia around the surgical incision 24 h after surgery (cm\^2) will be checked.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
108
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group DHRDesfluraneAdminister desflurane at 1 MAC, adjusting the dose by 1 vol% titration to maintain MAP and BIS levels, and remifentanil at 0.3 µg/kg/min.
Group DHRRemifentanilAdminister desflurane at 1 MAC, adjusting the dose by 1 vol% titration to maintain MAP and BIS levels, and remifentanil at 0.3 µg/kg/min.
Group DLRDesfluraneAdminister desflurane at 1 MAC, adjust the dose by 1 vol% titration to maintain MAP and BIS levels, and remifentanil at 0.025 µg/kg/min.
Group DLRRemifentanilAdminister desflurane at 1 MAC, adjust the dose by 1 vol% titration to maintain MAP and BIS levels, and remifentanil at 0.025 µg/kg/min.
Group RHRRemimazolamAdminister remimazolam at a dose of 6 mg/kg/h initially, followed by 1 mg/kg/h, and remifentanil at 0.3 µg/kg/min.
Group RHRRemifentanilAdminister remimazolam at a dose of 6 mg/kg/h initially, followed by 1 mg/kg/h, and remifentanil at 0.3 µg/kg/min.
Primary Outcome Measures
NameTimeMethod
The mechanical hyperalgesia thresholdat 24 hours after surgery

The mechanical hyperalgesia threshold (g/mm\^2) (preoperative) and 2 cm from the single port incision site (postoperative) at four points (horizontally and perpendicularly).

Secondary Outcome Measures
NameTimeMethod
Area of hyperalgesia around surgical incision24 hours after surgery

Area of hyperalgesia around surgical incision (cm\^2)

Time to first postoperative analgesic requirementWithin 1 hour after surgery

Time to first postoperative analgesic requirement (min)

Pain intensity24 hours after surgery

The Visual analogue scales (VAS)-100 is a line with words describing the extremes of pain from "no pain" to "worst imaginable pain".

Injected PCA volume containing morphine for 24 h after surgery24 hours after surgery

Injected PCA volume containing morphine for 24 h after surgery (ml)

Trial Locations

Locations (2)

Wonkwag UH

🇰🇷

Iksan, Jeollabukdo, Korea, Republic of

Wonkwang University hospital

🇰🇷

Iksan, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath